Latest News

Ivosidenib receives FDA approval to treat acute myeloid leukemia patients with IDH1 mutation

Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation.

Source link

Related posts

Medical News Today: Fibromyalgia: Many may receive wrong diagnosis


The Avoca Group Announces Keynote Speaker for 8th Annual Avoca Global Summit


Alcohol exposure during pregnancy linked with dose-dependent increase in miscarriage risk


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy